#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis lung ROHHAD syndrome Meningococcal immunisation Alexander disease Neuropathy peripheral B-cell small lymphocytic lymphoma recurrent Bulbospinal muscular atrophy congenital Tourette's disorder Amyotrophic lateral sclerosis Cutaneous T-cell lymphoma refractory Partial lipodystrophy Ichthyosis Myelin oligodendrocyte glycoprotein antibody-associated disease Huntington's disease Short stature homeobox gene mutation More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome X-linked lymphoproliferative syndrome – Basic Information Short-bowel syndrome – Treatment Combined immunodeficiency – Basic Information Malignant fibrous histiocytoma – Basic Information Ewing’s sarcoma metastatic – Basic Information Anaplastic thyroid cancer – Life with Disease Haemophilia A without inhibitors – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Idiopathic inflammatory myopathy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tilmanocept 89ZR-CED88004S Acoramidis Domperidone Dostarlimab Oleclumab Dazucorilant Fulvestrant L-Lysine Acetate Felis Domesticus (555) Mva-209-Fsp-B1 Lidocaine Hydrochloride ACETYLCARNITINE HYDROCHLORIDE Crgd-Zw800-1 Gefitinib Db-Oto-5 Glucose Phenylephrine Hydrochloride Gsk3915393 Futibatinib More therapies…

    Learn about Your Condition

    Vertebrobasilar stroke Joint stabilisation Optic glioma Head and neck cancer stage IV VEXAS syndrome Drug dependence Type 2 diabetes mellitus Laryngeal cancer stage II Partial lipodystrophy Post procedural swelling Alpha-1 antitrypsin deficiency Hepatic neoplasm Ocular lymphoma Thyroid mass Anal squamous cell carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    • Neoplasm malignant
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Irinotecan
    Belgium France Italy The Netherlands Spain

  • Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Blinatumomab
    • Isatuximab
    • Ponatinib
    Belgium France

  • A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Amivantamab
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Italy The Netherlands +3

  • Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Austria Belgium Estonia France Ireland Italy +1

  • Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Elacestrant
    • Exemestane
    Belgium Cyprus France Germany Greece Ireland +5

  • Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Docetaxel
    • Telisotuzumab Vedotin
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study Comparing Mosunetuzumab and Lenalidomide with Other Treatments for Patients with Relapsed or Refractory Marginal Zone Lymphoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma refractory
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Belgium France Germany Italy Portugal

  • ImmunoPET with 89Zr‑trastuzumab to predict response to trastuzumab deruxtecan in patients with locally advanced or metastatic breast cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer
    Belgium

  • Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    • Ductal adenocarcinoma of pancreas
    • Gastric cancer
    Investigated Drugs:
    • Glatiramer Acetate
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    Belgium Denmark France Germany Italy The Netherlands +1

  • Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Fulvestrant
    • Ly3484356
    Belgium France Hungary Ireland Poland Portugal +2
Previous Page
1 … 8 9 10 11 12 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!